MicroRNAs Involved in Anti-Tumour Immunity

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2013 Mar 13

PMID 23478435

Citations 6

Authors

Hong W H Yu

Daniel M Y Sze

William C S Cho

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs) are a category of small RNAs that constitute a new layer of complexity to gene regulation within the cell, which has provided new perspectives in understanding cancer biology. The deregulation of miRNAs contributes critically to the development and pathophysiology of a number of cancers. miRNAs have been found to participate in cell transformation and multiplication by acting as tumour oncogenes or suppressors; therefore, harnessing miRNAs may provide promising cancer therapeutics. Another major function of miRNAs is their activity as critical regulatory vehicles eliciting important regulatory processes in anti-tumour immunity through their influence on the development, differentiation and activation of various immune cells of both innate and adaptive immunity. This review aims to summarise recent findings focusing on the regulatory mechanisms of the development, differentiation, and proliferative aspects of the major immune populations by a diverse profile of miRNAs and may enrich our current understanding of the involvement of miRNAs in anti-tumour immunity.

Citing Articles

MicroRNAs Expression Patterns Predict Tumor Mutational Burden in Colorectal Cancer.

Huang J, Liu H, Zhao Y, Luo T, Liu J, Liu J Front Oncol. 2021; 10:550986.

PMID: 33634010 PMC: 7900489. DOI: 10.3389/fonc.2020.550986.

MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers.

Yang Y, Alderman C, Sehlaoui A, Xiao Y, Wang W Can J Gastroenterol Hepatol. 2018; 2018:9740357.

PMID: 30046565 PMC: 6038585. DOI: 10.1155/2018/9740357.

MicroRNAs as Biomarkers in Colorectal Cancer.

Masuda T, Hayashi N, Kuroda Y, Ito S, Eguchi H, Mimori K Cancers (Basel). 2017; 9(9).

PMID: 28902152 PMC: 5615339. DOI: 10.3390/cancers9090124.

MicroRNAs: Novel immunotherapeutic targets in colorectal carcinoma.

Li X, Nie J, Mei Q, Han W World J Gastroenterol. 2016; 22(23):5317-31.

PMID: 27340348 PMC: 4910653. DOI: 10.3748/wjg.v22.i23.5317.

MicroRNA-30c-1-3p is a silencer of the pregnane X receptor by targeting the 3'-untranslated region and alters the expression of its target gene cytochrome P450 3A4.

Vachirayonstien T, Yan B Biochim Biophys Acta. 2016; 1859(9):1238-1244.

PMID: 27085140 PMC: 4975670. DOI: 10.1016/j.bbagrm.2016.03.016.

References

Lin Z, Flemington E . miRNAs in the pathogenesis of oncogenic human viruses. Cancer Lett. 2010; 305(2):186-99. PMC: 3023823. DOI: 10.1016/j.canlet.2010.08.018. View

Bonifer C, Bowen D . Epigenetic mechanisms regulating normal and malignant haematopoiesis: new therapeutic targets for clinical medicine. Expert Rev Mol Med. 2010; 12:e6. DOI: 10.1017/S1462399410001377. View

Ghiringhelli F, Rebe C, Hichami A, Delmas D . Immunomodulation and anti-inflammatory roles of polyphenols as anticancer agents. Anticancer Agents Med Chem. 2012; 12(8):852-73. DOI: 10.2174/187152012802650048. View

Li J, Guo Y, Liang X, Sun M, Wang G, De W . MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4. J Cancer Res Clin Oncol. 2012; 138(5):763-74. DOI: 10.1007/s00432-012-1154-x. View

Koralov S, Muljo S, Galler G, Krek A, Chakraborty T, Kanellopoulou C . Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell. 2008; 132(5):860-74. DOI: 10.1016/j.cell.2008.02.020. View

Matsuyama H, Suzuki H, Nishimori H, Noguchi M, Yao T, Komatsu N . miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. Blood. 2011; 118(26):6881-92. DOI: 10.1182/blood-2011-05-354654. View

Cho W . Circulating MicroRNAs as Minimally Invasive Biomarkers for Cancer Theragnosis and Prognosis. Front Genet. 2012; 2:7. PMC: 3268566. DOI: 10.3389/fgene.2011.00007. View

Costinean S, Sandhu S, Pedersen I, Tili E, Trotta R, Perrotti D . Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood. 2009; 114(7):1374-82. PMC: 2727407. DOI: 10.1182/blood-2009-05-220814. View

Bazzoni F, Rossato M, Fabbri M, Gaudiosi D, Mirolo M, Mori L . Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals. Proc Natl Acad Sci U S A. 2009; 106(13):5282-7. PMC: 2664036. DOI: 10.1073/pnas.0810909106. View

10.

Vigorito E, Perks K, Abreu-Goodger C, Bunting S, Xiang Z, Kohlhaas S . microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity. 2007; 27(6):847-59. PMC: 4135426. DOI: 10.1016/j.immuni.2007.10.009. View

11.

Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, Kim J . Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res. 2010; 70(2):621-31. DOI: 10.1158/0008-5472.CAN-09-2340. View

12.

Cubillos-Ruiz J, Baird J, Tesone A, Rutkowski M, Scarlett U, Camposeco-Jacobs A . Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res. 2012; 72(7):1683-93. PMC: 3319850. DOI: 10.1158/0008-5472.CAN-11-3160. View

13.

Gantier M, Stunden H, McCoy C, Behlke M, Wang D, Kaparakis-Liaskos M . A miR-19 regulon that controls NF-κB signaling. Nucleic Acids Res. 2012; 40(16):8048-58. PMC: 3439911. DOI: 10.1093/nar/gks521. View

14.

Kosaka N, Iguchi H, Ochiya T . Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010; 101(10):2087-92. PMC: 11159200. DOI: 10.1111/j.1349-7006.2010.01650.x. View

15.

Rodrigues A, Dinis J, Gromicho M, Martins C, Laires A, Rueff J . Genomics and cancer drug resistance. Curr Pharm Biotechnol. 2011; 13(5):651-73. DOI: 10.2174/138920112799857549. View

16.

Nana-Sinkam S, Croce C . MicroRNA in chronic lymphocytic leukemia: transitioning from laboratory-based investigation to clinical application. Cancer Genet Cytogenet. 2010; 203(2):127-33. DOI: 10.1016/j.cancergencyto.2010.09.007. View

17.

Kimura S, Naganuma S, Susuki D, Hirono Y, Yamaguchi A, Fujieda S . Expression of microRNAs in squamous cell carcinoma of human head and neck and the esophagus: miR-205 and miR-21 are specific markers for HNSCC and ESCC. Oncol Rep. 2010; 23(6):1625-33. DOI: 10.3892/or_00000804. View

18.

ONeill L . How Toll-like receptors signal: what we know and what we don't know. Curr Opin Immunol. 2005; 18(1):3-9. DOI: 10.1016/j.coi.2005.11.012. View

19.

Lodish H, Zhou B, Liu G, Chen C . Micromanagement of the immune system by microRNAs. Nat Rev Immunol. 2008; 8(2):120-30. DOI: 10.1038/nri2252. View

20.

Visone R, Croce C . MiRNAs and cancer. Am J Pathol. 2009; 174(4):1131-8. PMC: 2671346. DOI: 10.2353/ajpath.2009.080794. View